Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

NDAQ:INO - Post by User

Inovio Pharmaceuticals Inc

Bullboard Posts

Post by TheRally69on May 26, 2020 12:48pm

127 Views

Post# 31073639

Buy mcig

Newly formed company gona rename Bot Inc. new crypto technology. But it's the hemp field bringing them 600 percent revenue this year stock is under valued Higley could be twenty folds soon. Buy some today enjoy 3 cents

Bullboard Posts

Visionstate set to leverage success in the U.S. market